Dr. Vikas K. Singh, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 340
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 48037 -
Internal Medicine Physician
KY license 48037
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Louisville Louisville, KY
- Baptist Health Hardin Elizabethtown, KY
- Baptist Health Floyd New Albany, IN
- Baptist Health Lagrange La Grange, KY
Medical groups
- Baptist Health Medical Group Inc (2,472 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 340
- Services billed
- 1,639
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 549 | 147 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 152 | 71 |
| Established patient office or other outpatient visit, 30-39 minutes | 121 | 91 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 99 | 60 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 64 | 63 |
| New patient office or other outpatient visit, 60-74 minutes | 62 | 62 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 25 | 21 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 16 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Louisville, KY | 91 |
| Gabapentin Other prescribers in Louisville, KY | 87 |
| Dexamethasone Other prescribers in Louisville, KY | 82 |
| Oxycodone Hcl Other prescribers in Louisville, KY | 76 |
| Potassium Chloride Other prescribers in Louisville, KY | 43 |
| Eliquis (apixaban) Other prescribers in Louisville, KY | 42 |
| Ondansetron Hcl Other prescribers in Louisville, KY | 40 |
| Abiraterone Acetate | 34 |
| Tramadol Hcl Other prescribers in Louisville, KY | 33 |
| Anastrozole Other prescribers in Louisville, KY | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 44 payments worth $4,589 in total to this clinician.
| Eisai Inc. | $2,016 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $1,698 |
| Bayer HealthCare Pharmaceuticals Inc. | $238 |
| Novartis Pharmaceuticals Corporation | $205 |
| Astellas Pharma US Inc | $85.40 |
| Pfizer Inc. | $76.40 |
| Novo Nordisk Inc | $46.83 |
| Daiichi Sankyo Inc. | $46.42 |
| Consulting Fee | $3,675 |
|---|---|
| Food and Beverage | $894 |
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Oct 8, 2025 | Consulting Fee Lenvima · Oncology | $2,000 |
| AstraZeneca Pharmaceuticals LP Jun 3, 2025 | Consulting Fee | $1,675 |
| Aveo Pharmaceuticals, Inc. Jan 17, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $229 in research payments for these studies, mostly to the institutions running them.
- A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.